{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-090891","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.983565+00:00","generated_at":"2026-06-11T11:49:33.958801+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioXcel Therapeutics Q2 net loss widens to $53.5M; cuts workforce 58%, cash runway to mid-2024","bullets":["Net loss of $53.5M in Q2 2023 vs $37.7M in Q2 2022; revenue of $457K from IGALMI.","Workforce reduction from ~190 to 80 employees; annualized cash burn reduced to ~$80M.","Cash and equivalents $127.5M as of June 30; runway extended to mid-2024 without new capital.","Requested FDA meeting to discuss TRANQUILITY II sNDA for BXCL501 in Alzheimer's agitation.","SERENITY III Part 2 protocol amendment to evaluate 80 mcg dose for at-home use in schizophrenia/bipolar."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-090891","json":"https://secwatch.observer/filing/0001104659-23-090891.json","markdown":"https://secwatch.observer/filing/0001104659-23-090891.md","text":"https://secwatch.observer/filing/0001104659-23-090891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923090891/0001104659-23-090891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923090891/tm2323591d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:49:33.958801+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9b0d2c6c646457fdbf6f1631d854bffe7b63cd7","claim":"BioXcel Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, BioXcel Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923090891/0001104659-23-090891-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}